GlassScriptPhysician profile
Joe L Buford
NPI 1942360052
$8,866.17
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,994 · 2020: $2,689 · 2021: $3,339 · 2022: $845.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,240.97 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $885.02 | 2019-2022 | |
| Amarin Pharma, INC. | $685.95 | 2019-2022 | |
| Gilead Sciences, INC. | $579.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $463.41 | 2019-2022 | |
| Abbvie INC. | $444.23 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $416.63 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.87 | 2019-2022 | |
| Esperion Therapeutics, INC. | $370.83 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $359.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $326.40 | 2019-2022 | |
| Pfizer INC. | $305.38 | 2019-2022 | |
| Lilly USA, LLC | $273.66 | 2020-2022 | |
| Allergan, INC. | $246.78 | 2019-2020 | |
| Novo Nordisk INC | $226.54 | 2019-2022 |
Show all 42 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Buford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.